N
KYMR icon

Nuveen’s Kymera Therapeutics KYMR Stock Holding History

Nuveen’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.7M Buy
128,091
+3,041
+2% +$241K ﹤0.01% 1511
2025
Q4 		$9.73M Buy
125,050
+18,345
+17% +$1.24M ﹤0.01% 1569
2025
Q3 		$6.04M Buy
106,705
+6,258
+6% +$282K ﹤0.01% 1814
2025
Q2 		$4.38M Sell
100,447
-42,791
-30% -$1.47M ﹤0.01% 1944
2025
Q1 		$3.92M Buy
143,238
+13
+0% +$474 ﹤0.01% 2040
2024
Q4 		$5.76M Buy
143,225
+3,038
+2% +$137K ﹤0.01% 1916
2024
Q3 		$6.64M Buy
140,187
+399
+0.3% +$17.6K ﹤0.01% 1853
2024
Q2 		$4.17M Buy
139,788
+43,793
+46% +$1.52M ﹤0.01% 2039
2024
Q1 		$3.86M Sell
95,995
-40,831
-30% -$1.46M ﹤0.01% 2112
2023
Q4 		$3.48M Buy
136,826
+41,962
+44% +$750K ﹤0.01% 2149
2023
Q3 		$1.32M Sell
94,864
-1,006
-1% -$20.2K ﹤0.01% 2461
2023
Q2 		$2.2M Sell
95,870
-18,531
-16% -$531K ﹤0.01% 2300
2023
Q1 		$3.39M Sell
114,401
-9,384
-8% -$303K ﹤0.01% 2103
2022
Q4 		$3.09M Sell
123,785
-15,850
-11% -$423K ﹤0.01% 2182
2022
Q3 		$3.04M Buy
139,635
+12,851
+10% +$339K ﹤0.01% 2171
2022
Q2 		$2.5M Buy
126,784
+19,552
+18% +$457K ﹤0.01% 2326
2022
Q1 		$4.35M Sell
107,232
-3,674
-3% -$155K ﹤0.01% 2134
2021
Q4 		$5.83M Sell
110,906
-6,055
-5% -$353K ﹤0.01% 2031
2021
Q3 		$7.36M Sell
116,961
-19,920
-15% -$1.15M ﹤0.01% 1998
2021
Q2 		$6.64M Buy
136,881
+97,387
+247% +$4.23M ﹤0.01% 2098
2021
Q1 		$1.53M Buy
39,494
+661
+2% +$39.8K ﹤0.01% 2730
2020
Q4 		$2.41M Buy
+38,833
New +$1.89M ﹤0.01% 2414

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Nuveen's KYMR Position: Q1 2026 in Review

Nuveen increased its Kymera Therapeutics (KYMR) stake by 2.4% in Q1 2026, buying an estimated $241K and bringing the position to 128,091 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Nuveen first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Nuveen held 128,091 shares of Kymera Therapeutics worth $10.7M as of Q1 2026.
  • Nuveen bought 3,041 Kymera Therapeutics shares in Q1 2026, an estimated $241K.
  • Kymera Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1511 holding.
  • Nuveen first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.